Daniel Dubois withdraws from IBF final eliminator with Frank Sanchez to fight for a mandatory shot at Oleksandr Usyks world ...

Martin Bakole and Efe Ajagba – heavyweights who stood, albeit shakily, only a step or two away from the biggest fights in the division – both needed a decisive performance to advance their careers ...

There's a whole world under the surface and only Ron has any idea about it. And sometimes the two worlds collide, and sometimes they don't. Ron holds them at arm's length from each other. Watch every ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent ...

MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver ...

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

- Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W ...

David's Refuge hosts ROC for Caregivers, highlighting support for special needs parents Rochester, N.Y. — David's Refuge hosted its annual ROC for Caregivers event on Wednesday at Comedy at the ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine ...

– Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025 – – Initiated Phase 1 healthy adult trial of EDG-15400 for ...

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and ...